Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26074| Title: | Report dose-to-medium in clinical trials where available; a consensus from the global Harmonisation group to maximize consistency. | Austin Authors: | Kry, Stephen F;Lye, Jessica ;Clark, Catharine H;Andratschke, Nicolaus;Dimitriadis, Alexis;Followill, David;Howell, Rebecca;Hussein, Mohammad;Ishikawa, Masayori;Kito, Satoshi;Kron, Tomas;Lee, Jonny;Michalski, Jeff;Filippo Monti, Angelo;Reynaert, Nick;Taylor, Paige;Venables, Karen;Xiao, Ying;Lehmann, Joerg | Affiliation: | Imaging and Radiation Oncology Core, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. European Organisation for Research and Treatment of Cancer (EORTC), Department of Medical Physics, ASST GOM Niguarda Hospital, Milan, Italy Australian Clinical Dosimetry Service, Australian Radiation Protection and Nuclear Safety Agency, Melbourne, Australia Olivia Newton-John Cancer Wellness and Research Centre Trans Tasman Radiation Oncology Group (TROG), Newcastle, NSW, Australia Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Radiation Oncology Department, Calvary Mater Newcastle, Newcastle, NSW, Australia School of Mathematical and Physical Sciences, University of Newcastle, Newcastle, NSW, Australia Institute of Medical Physics, University of Sydney, Sydney, NSW, Australia NIHR Radiotherapy Trials Quality Assurance Group, University College London Hospital, University College London, National Physical Laboratory United Kingdom European Organisation for Research and Treatment of Cancer Radiotherapy Quality Assurance Group, University Hospital of Zurich, University of Zurich, Zurich, Switzerland Dosimetry and Medical Radiation Physics Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria Imaging and Radiation Oncology Core, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Radiation Dosimetry Services, The University of Texas MD Anderson Cancer Center, Houston TX, United States National Physical Laboratory United Kingdom Japan Clinical Oncology Group, Faculty of Health Sciences, Hokkaido University, Japan Japan Clinical Oncology Group, Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital NIHR Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Northwood, United Kingdom Imaging and Radiation Oncology Core, Washington University School of Medicine, St. Louis, MO, United States European Organisation for Research and Treatment of Cancer, Medical Physics Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium Imaging and Radiation Oncology Core, The University of Texas MD Anderson Cancer Center, Houston, TX, United States NIHR Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Northwood, United Kingdom Imaging and Radiation Oncology Core, University of Pennsylvania, Philadelphia, PA, United States |
Issue Date: | Jun-2021 | Date: | 2021-03-16 | Publication information: | Radiotherapy and Oncology 2021; 159: 106-111 | Abstract: | To promote consistency in clinical trials by recommending a uniform framework as it relates to radiation transport and dose calculation in water versus in medium. The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonisation Group (GHG; www.rtqaharmonization.org) compared the differences between dose to water in water (Dw,w), dose to water in medium (Dw,m), and dose to medium in medium (Dm,m). This was done based on a review of historical frameworks, existing literature and standards, clinical issues in the context of clinical trials, and the trajectory of radiation dose calculations. Based on these factors, recommendations were developed. No framework was found to be ideal or perfect given the history, complexity, and current status of radiation therapy. Nevertheless, based on the evidence available, the GHG established a recommendation preferring dose to medium in medium (Dm,m). Dose to medium in medium (Dm,m) is the preferred dose calculation and reporting framework. If an institution's planning system can only calculate dose to water in water (Dw,w), this is acceptable. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26074 | DOI: | 10.1016/j.radonc.2021.03.006 | ORCID: | Journal: | Radiotherapy and Oncology | PubMed URL: | 33741471 | Type: | Journal Article | Subjects: | Clinical trial Dose calculation Dose medium GHG Radiation dosage |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.